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Summary
BACKGROUND: Iron deficiency anaemia is a common
disease with a prevalence of up to 19.2% in populations
at risk. However, the prevalence of iron deficiency (ID) in
hospitalised patients is not well known. The aims of this
retrospective, observational cohort study were to evaluate
the current diagnostic procedures for, and treatment of, ID
as well as to estimate the prevalence of undiagnosed ID in
hospitalised patients at the division of internal medicine in
a Swiss tertiary university referral centre.
METHODS: Within a study period of 6 months, data from
all patients hospitalised at the division of internal medicine
were analysed for the presence of anaemia (defined as
haemoglobin levels for males <130 g/l and for females
<120 g/l) and ID (ferritin <15 µg/l or ferritin <50 µg/l and
transferrin saturation <20%).
RESULTS: A total of 2,781 hospitalisation cases were ana-
lysed (2,251 unique patients, male 55.5%, mean age 66.4
years). In 2,267 cases (81.5%) results of a red blood cell
count were available. In 329 cases (14.5%) iron parameters
(IP) were determined and 45 (13.7%) cases / unique pa-
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tients with ID were detected. Among the remaining 1,938
cases without IP determination, statistical estimation pre-
dicted 103 (56‒329) undiagnosed ID cases. In ID patients,
the most prevalent diagnosis was heart failure (24.4%). Of
these patients, 72.7% had haemorrhage-facilitating drugs
on hospital admission or discharge.
CONCLUSION: Iron deficiency is common in internal
medicine and up to two-thirds of cases may not be dia-
gnosed. Every seventh patient who had iron parameters
analysed was iron deficient and two-thirds of patients with
ID were treated with intravenous iron.
Key words: iron deficiency; anaemia; in-hospital; internal
medicine; iron supplementation; Switzerland
Background
Iron deficiency anaemia is common in the general popula-
tion; a US population study found a prevalence of 2% to
5% affecting above all toddlers, adolescent girls and young
women of childbearing age [1]. In the population above
the age of 50 years, this US study found a prevalence of
iron deficiency (ID) of 2% (50–69 years) to 4% (≥70 years)
in males and 5% (50–69 years) to 7% (≥70 years) in fe-
males [1]. A European study found a prevalence of iron de-
ficiency of 19.3% in young females at the age of 17 to 38
years (serum ferritin <15 μg/l) [2].
The prevalence of ID in hospitalised patients is not very
well known and may be significantly higher among
severely ill patients and patients with chronic illnesses, de-
pending on the type of illness, its severity, co-morbidities
and treatment modalities. Therefore, we planned a study to
estimate the prevalence of ID and to elucidate the current
practice in diagnosis and treatment of ID in hospitalised pa-
tients at the division of internal medicine of a Swiss tertiary
patient referral centre.
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Methods
The study was designed as a single centre, retrospective
observational cohort study including all inpatients of four
wards of the division of internal medicine at a tertiary refer-
ral university hospital in north-western Switzerland. Basel
University hospital has 660 beds treating about 31,000 pa-
tients on an in-patient basis and 176,000 in the ambulatory
setting per year. The division of internal medicine consists
of 185 beds treating around 8,000 hospitalised patients per
year. The predominant medical specialties are gastroen-
terology, cardiology, pneumology, haematology, infectious
disease, nephrology and oncology.
Study participants
All consecutive hospitalisations of patients ≥18 years of
age on the four wards in the division of internal medicine
with a blood draw between July 1st and December 31st
2011 were screened. Only hospitalisation cases with a red
blood cell count (RBCC) within the study period were in-
cluded in the analysis (see fig. 1). Per patient, more than
one hospitalisation was accepted within the given time
frame. Hospitalisation cases were assigned either to the
group “iron parameters available” or to the group “no iron
parameters available”. As a minimal requirement for the
group “iron parameters available” at least one ferritin value
had to be available.
Outcome parameters
Primary: The number of patient cases with ferritin <15 µg/l
or ferritin <50 µg/l and transferrin saturation <20% who
were diagnosed or not diagnosed as ID.
Secondary: The number of IP measurements and mean res-
ults according to subgroups; the number of diagnoses of ID
or iron deficiency anaemia (IDA) that were retained in the
patient file as well as the number and modalities of treat-
ment.
Figure 1
Case inclusion algorithm.
* At least ferritin was determined. †Indices = cellular indices such
as haemoglobin, mean corpuscular volume (MCV) or the mean
cellular haemoglobin concentration (MCHC) ‡ Basic parameters:
age, gender, main diagnosis, results of red blood cell count (RBCC)
§ Number of patients with and without iron parameters do not add
up to 1930, because 74 patients had in some cases iron
parameters determined and in others not.
Subgroups consisted of the main diagnosis, age, sex, pres-
ence of inflammation and the presence of anaemia with
its subdivisions according to erythrocyte mean corpuscular
volume (MCV) and mean corpuscular haemoglobin con-
centration (MCHC).
Diagnoses: The primary diagnoses as well as up to 11
secondary diagnoses as coded in ICD-10 according to the
World Health Organisation (WHO; www.who.int/classific-
ations/icd/icdonlineversions, last accessed April 4th, 2013)
were pulled from the administrative data records.
Definitions are depicted in table 1.
Data collection
Data was extracted from the laboratory information system
(LIS; Dorner Health IT Solutions, Müllheim, Germany) in
patients with documented RBCC and, subsequently, with
documented iron parameters (see fig. 1).
Data collected for patients with only RBCC included: age,
gender, main and side diagnoses, results of RBCC with
RBC indices (mean corpuscular volume, mean corpuscular
haemoglobin, mean corpuscular haemoglobin concentra-
tion, haematocrit and reticulocytes).
If several blood samples were drawn during a hospitalisa-
tion, the results of the first blood sample taken were extrac-
ted for study purpose.
Data collection for patients with known ID parameters in-
cluded, wherever possible, iron, ferritin, total iron binding
capacity, transferrin and transferrin saturation and the sol-
uble transferring receptor as well as the C-reactive protein
(CRP). Treatment of ID included oral or intravenous iron
preparations, concomitant erythropoietin and/or applica-
tion of packed erythrocyte concentrates (ECs).
Statistical analysis
Continuous variables are reported as number of cases,
mean, standard deviation, median, minimum and maxim-
um. Frequencies and percentages are reported for categor-
ical variables. Differences between subgroups were tested
using the t-test for continuous and Fisher’s exact test for
categorical variables, respectively. When appropriate, per-
centages are reported together with a 95% confidence in-
terval (95%CI) according to Blaker (2000) [3].
An approximate estimate of the number of undiagnosed
iron deficiency cases in the subset of cases with unknown
iron parameters was calculated as follows: Since in the
study cohort iron deficiency was almost exclusively ac-
companied by anaemia, we restricted the estimation of the
number of undiagnosed cases on anaemic patients (a con-
servative assumption). Fishers’ exact test was used to com-
pare ID frequencies in different subgroups (sex, age, an-
aemia, cell types, inflammation, renal failure) and to com-
pare whether cases with and without iron parameters
differed concerning these subgroups. The probability of ID
(including 95% CI) given the patient is anaemic was calcu-
lated for all cell types (combinations of MCV and MCHC)
using the subset of patients with known iron parameters.
Then, these probabilities were multiplied by the number
of cases with anaemia per cell type in the subset with un-
known iron parameters, yielding the corresponding expec-
ted numbers of ID cases. Lower and upper bounds for the
estimated number of cases were calculated based on the
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95% confidence intervals. The expected total number of
undiagnosed cases is the sum over all cases per cell type
(again a point estimate with lower and upper bounds). All
analyses were conducted using the statistical software R,
version 2.15.1 [4].
Ethics committee
The local independent ethics committee (Ethics committee
Basel) approved of the study to ensure data safety in the
context of quality measurement; written patient consent
was waived.
Results
Population data
Within the observation period of six months, 2,781 hospit-
alisation cases were identified resulting from 2,251 unique
patients. In 2,267 cases from 1,930 unique patients (85.7%
of total patients, 81.5 % of total cases) results from at least
a red blood cell count were available (RBCC; fig. 1). Iron
parameters were analysed in 329 cases (14.5%; 319 unique
patients).
Patient and case characteristics and range of diagnosis of
the study population are summarised in table 2. Of 1,930
unique patients most were hospitalised once (n = 1,690,
87.6%). Diagnoses were retrieved for all cases; in 86 of
2,267 cases (3.8%) diagnoses were missing. On the base
levels of ICD-coding the most common main diagnoses
were diseases of the circulatory system (codes I00-I99;
24.0%), second neoplasms (codes C00-D49; 15.7%) and
third, diseases of the respiratory system (codes J00-J99;
12.2%).
Laboratory values
An overview over the basic laboratory parameters is depic-
ted in table 3.
Prevalence of anaemia with and without iron
deficiency
Of 2,267 cases with a RBCC, 1400 (61.8%, 95%CI:
59.7%–63.7%) showed anaemia defined as <130 g/l in
males and <120 g/l in females (<110 g/l if pregnant) ac-
cording to WHO standards. Based on these definitions,
in our cohort females were less often anaemic (n = 591,
58.3%, 95%CI: 55.2%–61.3%]) than males (n = 809,
Table 1: Definitions.
Parameter Definition
Iron deficiency Ferritin <50 µg/l and transferrin saturation <20% or ferritin <15 µg/l [18, 19]
Anaemia Males: HB <130 g/l, females: <120 g/l (<110 g/l if pregnant) [20]
Signs for inflammation C-reactive protein >5 mg/l [11]
Renal failure Glomerular filtration rate (GFR)* <30 ml/min
Hypochromic-normochromic-hyperchromic MCHC cut-offs at 320 g/l and 360 g/l **
Microcytic-normocytic-macrocytic MCV cut-offs at 75 fl and 95 fl **
Soluble transferrin receptor Normal range at this medical centre 2.2–5.0 mg/L ***
* Glomerular filtration rate (GFR) was computed using the Modification of Diet in Renal Disease (MDRD) equation: GFR (mL/min per 1.73 m2) =186x (Serum Creatinine/
88.4)–1.154x(Age)–0.203 x (0.742 if female) x (1.210 if African-American) [21, 22].
** All definitions mentioned here are as used in this centre; these values may differ slightly in other medical laboratories such as mentioned by Thompson et al. (1988) [10].
*** measurement by immunoturbidimetric test with latex particle enhancement; for further discussion of utility see Mast et al. (1998) [11]
Serum creatinine was converted from µmol/L to mg/dl using (Scr/88.4)–1.154 instead of (Scr)–1.154 in order to comply with the calculation in the original papers by Levey et al.
(1999, 2003).
Table 2: Patient characteristics and range of diagnosis.
n = 1,930 patients n = 2,267 cases
Fraction male 1071 (55.5%)
Age (mean) 66.4 (±16.5) years
Number of visits in study period
1 1690 (87.6%)
2 177 (9.2%)
>2 63 (3.2%)
Main diagnosis (ICD-10)
I00-I99: Diseases of the circulatory system 545 (24.0%)
C00-D49: Neoplasms 357 (15.7%)
J00-J99: Diseases of the respiratory system 277 (12.2%)
A00-B99: Certain infectious and parasitic diseases 261 (11.5%)
K00-K95: Diseases of the digestive system 193 (8.5%)
N00-N99: Diseases of the genitourinary system 120 (5.3%)
G00-G99: Diseases of the nervous system 77 (3.4%)
E00-E89: Endocrine, nutritional and metabolic diseases 62 (2.7%)
M00-M99: Diseases of the musculoskeletal system and connective tissue 62 (2.7%)
S00-T88: Injury, poisoning and certain other consequences of external causes 59 (2.6%)
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 56 (2.5%)
Others 168 (7.4%)
No ICD coding information available 86 (3.8%)
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64.6%, 95%CI: 61.9%–67.2%). None of the pregnant pa-
tients (n = 10) in our cohort was anaemic as defined. There
were <1% of measurements with a haematocrit <20% (22/
2267 cases), where we suspect dilution (e.g. blood drawn
from the infusion arm).
Of 329 cases (319 unique patients) with iron parameters
determined, 45 (13.7%, 95%CI: [10.2%–17,8%]) cases/
unique patients with iron deficiency (ID) were detected. In
284 cases (86.3%) ID could be ruled out (either ferritin ≥50
µg/l or ferritin ≥15 µg/l together with transferrin saturation
≥20%). A total of 16 out of 45 patients (36.5%) with ID
were identified based on the definition ferritin <15 µg/l and
44 patients (97.8%) based on the definition ferritin <50 µg/l
and transferrin saturation <20%. All patients with ferritin
<15 µg/l also showed a transferrin saturation <20% such
that the latter definition would include all ID cases (in one
patient transferrin saturation was not measured).
The soluble transferrin receptor (STFR) showed consider-
able overlap between patients with and without ID: in 35
of 45 cases with ID (STFR was not determined for one ID
case) the marker was elevated (i.e. STFR >5 mg/l; 78.4%,
95%CI: 65.1%–89.2%). In 250 cases with no ID (STFR
was not determined for 34 cases) the marker was low in
194 cases (77.6%, 95%CI: 72.1%–82.5%).
Prevalence of renal failure
Renal failure (RF) is usually associated with anaemia and
a high iron demand. In this study, creatinine was available
in 2,260 hospitalisation cases (99.7%), whereof 220 cases
(9.7%, 95%CI: 8.6%–11.0%) showed a glomerular filtra-
tion rate (GFR) <30 ml/min meeting the definition of RF as
suggested by Guralnik et al. (2004) [5]. The prevalence of
RF did not differ between male (122/1250, 9.7%) and fe-
male patients (98/1010, 9.7%).
Prevalence of inflammation
C-reactive protein (CRP) was available in 2245 cases
(99.0%; 22 measurements missing), whereof 1786 cases
(79.5%, 95%CI: 77.8%–81.2%) showed signs of inflam-
mation (CRP >5 mg/l).
In cases of inflammation, significantly less ID was detec-
ted. In cases with signs of inflammation, only 9.9% (25/252
cases) showed ID as compared to 27.0% (20/74 cases) of
cases without inflammation (p <0.001).
Iron deficiency in combination with anaemia, renal
failure and inflammation
ID was almost always accompanied by anaemia; only one
patient (equalling one case) out of 45 with iron deficiency
(2.2%) did not show any signs of anaemia in the RBCC.
Overall, 8.9% of cases/patients with ID showed renal fail-
ure defined as GRF <30 ml/min and 25 cases/patients
(55.6%) signs of inflammation. Of 266 cases with anaemia,
44 (16.5%) were iron deficient (see table 4).
Cellular indices: Mean corpuscular volume (MCV)
and mean corpuscular haemoglobin concentration
(MCHC) depending on ID status
Overall, cell types as described by the two cellular indices
MCV and MCHC differed significantly between patients
with ID and without (p <0.001). Compared with patients
without iron deficiency, ID patients had microcytic hypo-
chromic cells more often (26.7% vs 1.8%) and rarely had
macrocytic (4.4% vs 22.9%) or hyperchromic cells (4.4%
vs 22.2%). However, normocytic normochromic RBC was
the most common cell type in both groups (44.4% in pa-
tients with ID vs 53.2%), which renders the prediction of
ID based solely on cell indices difficult.
Approximate estimation of the number of undiagnosed
ID cases
The information on the presence or absence of anaemia as
well as on cell indices (MCV and MCHC) may be used to
estimate the probability of ID for a patient. Table 4 sum-
marises the number of cases with and without ID. We es-
timated the probability of ID for each cell type given that
the patient is anaemic. Although these estimates are based
on a limited number of 329 cases with known iron paramet-
ers and are not directly transferable to another population
with different prevalence, they allow some general conclu-
sions to be drawn: In our study population, the absence
of anaemia allows one to basically rule out ID since 62
out of 63 patients/cases without anaemia also did not have
ID (98.4%, 95%CI: 91.8%–99.9%). Also, rarely associated
with ID were macrocytic and hyperchromic cells with 65
out of 67 (97.5%, 95%CI: 90.1%–99.5%) and 56 out 58
(96.5, 95%CI: [88.5%–99.45) cases, respectively, not hav-
ing iron deficiency. Conversely, 12 out of 17 patients with
microcytic hypochromic cell had iron deficiency (70.6%,
95%CI: 45.6%–87.6%).
Consequently, we calculated an approximate estimate of
the number of undiagnosed ID cases in the remaining 1,938
cases without determination of iron parameters (IP; table
5). Cases with and without measured IP did not differ signi-
ficantly concerning gender, age and inflammation markers.
However, patients with IP suffered more often from renal
failure (14.6% vs 8.9%, p = 0.002), were more commonly
anaemic (80.8% vs 58.5%, p <0.001) and showed a signi-
ficant difference in the distribution of cell indices (p <0.001
for both MCV and MCHC). As opposed to the cell indices
and anaemia, renal failure was not significantly linked to
ID and was therefore not included in the prediction rule.
Restricting to anaemic patients reduced the set of candidate
cases from 1,938 to 1,134. Among those, 7 cases with mi-
crocytic hypochromic cells were identified which gave rise
to an expected number of 5 missed ID cases. The estim-
ated number of missed ID cases with normocytic normo-
chromic cells is 75. Overall, the expected number of undia-
gnosed ID cases was 103 (lower bound 56 and upper bound
329). This corresponds to 5.3% of the cases without iron
parameters determined as compared to 13.7% laboratory-
proven ID cases.
Classification of diseases and quality of iron deficiency
coding
Looking at the detailed diagnostic codes in patients with
ID, the most prevalent diagnoses were heart failure (I50.01;
24.4%), iron deficiency with secondary anaemia due to
blood loss (D50.0; 24.4 %) and iron deficiency anaemia
without further specification (D50.9; 24.4%, table 6). Com-
plications from drugs (Y57.9) figured next with 15.6% of
patients, and therefore adverse drug events account for a
Original article Swiss Med Wkly. 2013;143:w13847
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 4 of 9
substantial percentage of patients with laboratory proven
and correctly diagnosed iron deficiency anaemia.
On the base levels of ICD-coding the most common main
diagnoses in patients with ID were diseases of the circulat-
ory system (codes I00-I99), with 35.6% of the cases com-
pared with 24.0% in the entire study population (see table
2). Second and third most common disease groups were
diseases of the digestive system (code K00-K95; patients
with ID: 13.3%; study population: 8.5%) and diseases of
the blood and blood-forming organs and certain disorders
involving the immune mechanism (codes D50-D89; pa-
tients without ID: 11.1%, study population: 2.2%).
For iron deficiency, the following ICD-10 codes were used:
D50.0, D50.8, D50.9 and E61.1. Of cases with laboratory
proven ID, iron deficiency was coded in 27/45 cases (60%).
From 11 patients diagnosed with heart failure, 8 (72.7%)
had aspirin, oral anticoagulants (phenprocoumon) or hep-
arins on hospital admission or discharge.
Iron supplementation
Exactly two thirds of patients with laboratory proven iron
deficiency received iron supplementation (IS) of some kind
(30/45 patients, 66.6%). However, two of the 15 patients
without IS received packed ECs (one received one, the oth-
er two units, respectively).
Of the 30 patients receiving IS, 80% (24/30 patients) re-
ceived it by intravenous route, 16.6% (5/30 patients) orally
and one patient by combined intravenous and oral admin-
istration. All patients with intravenous IS received ferric
carboxymaltose. In one patient no information on the type
of ingredient applied was available. More than half of in-
travenously supplemented patients (13/24, 54.2%) received
packed ECs (range 1–4.5 units) additionally.
Discussion
Whereas anaemia is a well-recognised medical problem,
iron deficiency (ID) – although very common – is often
neglected; moreover its management is not well stand-
ardised, although guidelines exist for example in nephro-
logy [6]. In this study we elucidate the in-hospital manage-
ment of ID across different diseases mainly in the fields
of gastroenterology, cardiology, nephrology, oncology and
haematology.
More than 60% of the patients hospitalised were anaemic
in this university hospital; the prevalence was 5–6 times
Table 3: Basic laboratory parameters (excluding iron parameters).
Variable (units) Levels N Mean SD Median Min Max
Red blood cell count
HB [g/l] female 1014 114.31 19.81 115.00 57.00 179.00
male 1253 118.47 23.95 121.00 19.00* 206.00
all 2267 116.61 22.28 118.00 19.00* 206.00
HT [%] female 1014 0.33 0.06 0.33 0.17 0.52
male 1253 0.34 0.07 0.34 0.06* 0.58
all 2267 0.33 0.06 0.34 0.06* 0.58
EC [x1012/l] female 1014 3.72 0.68 3.76 1.85 6.22
male 1252 3.78 0.78 3.84 0.68 6.99
all 2266 3.75 0.74 3.80 0.68 6.99
MCV [fl] female 1014 88.59 7.01 88.40 58.70 121.00
male 1253 89.86 7.28 89.80 57.90 120.60
all 2267 89.29 7.19 89.20 57.90 121.00
MCH [pg] female 1014 30.89 2.73 31.10 18.00 44.10
male 1253 31.49 2.84 31.60 17.00 41.30
all 2267 31.22 2.81 31.40 17.00 44.10
MCHC [g/l] female 1014 348.65 14.61 350.00 268.00 402.00
male 1253 350.38 15.12 352.00 280.00 406.00
all 2267 349.61 14.91 351.00 268.00 406.00
RET [‰] female 217 23.79 18.44 20.00 1.00 126.00
male 301 25.95 23.76 20.00 1.00 188.00
all 518 25.04 21.70 20.00 1.00 188.00
Renal function
CR [µmol/l] female 1010 96.1 95.9 69.0 18.0 891.0
male 1250 121.5 124.6 85.0 21.0 1453.0
all 2260 110.1 113.4 78.0 18.0 1453.0
GFR [ml/min] female 1010 80.6 40.3 78.3 4.2 374.7
male 1250 85.7 44.9 83.3 4.1 472.0
all 2260 83.4 43.0 80.8 4.1 472.0
Inflammation
CRP [mg/l¨] female 1003 52.7 71.7 21.6 0.3 381.5
male 1242 61.7 75.0 30.4 0.3 408.4
all 2245 57.7 73.7 25.0 0.3 408.4
* There are <1% of measurements with a haematocrit <20%, where we suspect dilution (22/2267 cases with known haematocrit).
CRP = C-reactive protein; EC = erythrocytes; GFR = glomerular filtration rate; HB = haemoglobin; HT = haematocrit; CR = creatinine; MCV = mean corpuscular volume;
MCH = mean corpuscular haemoglobin; MCHC = mean corpuscular haemoglobin concentration; RET = reticulocytes
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higher than large surveys shown for the general population
[5, 7]. Thus, hospitalisation per se represents a selection to-
wards anaemia.
Another selection process seems to take place when phys-
icians receive their patients’ first laboratory analyses: an-
aemia and renal failure as defined here seem to trigger the
request for IPs. Our study supports this clinical reasoning.
The prevalence of measured iron deficiency (ID) in anaem-
ic patients was 16.5% in our cohort; compared to a US pop-
ulation survey by Guralnik et al. it was identical (2004;
16.6%) [5]. This high prevalence is not astonishing given
the frequent gastrointestinal blood loss and nutritional is-
sues such as concomitant vitamin B12 and folate deficien-
cies in these patients [5]. Furthermore, heart failure was the
most common diagnosis in our patients with ID; this may
on one hand reflect the influence of studies showing the be-
nefit of iron supplementation in these patients, such as the
one by Anker et al. (2009) and others [8, 9]. On the oth-
er hand, almost three out of four patients with heart fail-
ure were treated with aspirin, oral anticoagulants, heparins
or a combination of anticoagulants on admission as well
as on discharge. It may well be reasoned that drug-induced
gastrointestinal blood loss plays a major role in ID of pa-
tients with heart failure.
An approximate estimate of undiagnosed ID cases revealed
that about two thirds of ID cases may have been missed in
our patient sample. The estimate is potentially conservat-
ive since it is based on the assumption that ID comes along
Table 4: Cell indices and probability of iron deficiency in cases with known iron parameters, according to anaemia status (n = 329 cases).
Anaemia No Anaemia
Cell indices (MCV, MCHC) ID n (%) No ID n (%) ID n (%) No ID N (%) p(ID|anaemia) [95% CI]
Microcytic hypochromic 12 (27.3) 5 (2.2) 0 0 70.6 [45.6–87.6]
Microcytic normochromic 5 (11.4) 11 (5.0) 1 (100) 2 (3.2) 26.3 [11.0–50.0]
Microcytic hyperchromic 1 (2.3) 1 (0.4) 0 0 50.0 [2.5–97.5]
Normocytic hypochromic 3 (6.8) 6 (2.7) 0 1 (1.6) 30.0 [8.7–61.9]
Normocytic normochromic 20 (45.4) 122 (55.0) 0 29 (46.8) 11.7 [7.4–17.4]
Normocytic hyperchromic 1 (2.3) 27 (12.2) 0 15 (24.2) 2.3 [0.1–12.0]
Macrocytic hypochromic 0 2 (0.9) 0 0 0.0 [0.0–77.6]
Macrocytic normochromic 2 (4.5) 38 (17.1) 0 12 (19.4) 3.8 [0.7–12.8]
Macrocytic hyperchromic 0 10(4.5) 0 3(4.8) 0.0 [0.0–22.5]
Total 44 (100) 222 (100) 1 (100) 62 (100)
ID = iron deficiency; MCHC = mean corpuscular haemoglobin concentration; MCV = mean corpuscular volume; p(ID|anaemia) [95% CI]: probability of ID given that the
person has an anaemia [95% confidence interval]
Table 5: Cell indices and probability of iron deficiency, according to availability of iron parameters (all cases, n = 2,267).
Cell indices (MCV, MCHC) IP n (%) No IP n (%) No IP anaemia n (%) p(ID|anaemia) [95% CI] E(ID) [bounds]
Microcytic hypochromic 17 (5.2) 8 (0.4) 7 (0.6) 70.6 [45.6–87.6] 5 [3–6]
Microcytic normochromic 19 (5.8) 25 (1.3) 19 (1.7) 26.3 [11.0–50.0] 5 [2–9]
Microcytic hyperchromic 2 (0.6) 0 (0.0) 0 (0.0) 50.0 [2.5–97.5] 0 [0–0]
Normocytic hypochromic 10 (3.0) 21 (1.1) 20 (1.8) 30.0 [8.7–61.9] 6 [2–12]
Normocytic normochromic 171 (52.0) 1,069 (55.2) 641 (56.5) 11.7 [7.4–17.4] 75 [47–111]
Normocytic hyperchromic 43 (13.1) 470 (24.3) 224 (19.8) 2.3 [0.1–12.0] 5 [0–27]
Macrocytic hypochromic 2 (0.6) 17 (0.9) 13 (1.1) 0.0 [0.0–77.6] 0 [0–10]
Macrocytic normochromic 52 (15.8) 273 (14.1) 174 (15.3) 3.8 [0.7–12.8] 7 [1–22]
Macrocytic hyperchromic 13 (4.0) 55 (2.8) 36 (3.2) 0.0 [0.0–22.5] 0 [0–8]
Total 329 (100.0) 1,938 (100.0) 1,134 (100.0) 103 [56–329]
E(ID)[bounds]: Estimated number of ID cases among the population with unknown iron parameters [upper and lower bound of the prediction based on the 95% CI], ID =
iron deficiency, IP = with known iron parameters, no IP = iron parameters not known, no IP anaemia = patients with anaemia with unknown iron parameters. p(ID|anaemia)
[95% CI]: probability of ID given that the person has an anaemia [95% confidence interval]
Table 6: The ten most common diagnoses in patients with iron deficiency (n = 45).
ICD-10 code Definition Iron deficiency n (%)*
I50.01 Congestive heart failure 11 (24.4)
D50.0 Iron deficiency anaemia secondary to blood loss (chronic) 11 (24.4)
D50.9 Iron deficiency anaemia, unspecified 11 (24.4)
I10.90 Essential hypertension 10 (22.2)
Y57.9 Complications of drugs or medication, unspecified 7 (15.6)
N18.3 Chronic kidney disease, stage 3 (moderate) 6 (13.3)
E11.90 Type 2 diabetes mellitus without complications 6 (13.3)
I11.90 Hypertensive heart disease without heart failure 6 (13.3)
I25.19 Atherosclerotic heart disease, unspecified 5 (11.1)
I08.1 Rheumatic disorders of both mitral and tricuspid valves 5 (11.1)
E87.6 Hypokaalemia 5 (11.1)
D62 Acute post-haemorrhagic anaemia 5 (11.1)
D50.8 Other iron deficiency anaemias 5 (11.1)
* There may be more than one of these diagnoses per patient.
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with anaemia which is not necessarily the case in a differ-
ent subset of patients. This calls for increased attention to
clinical and laboratory signs of ID.
Ferritin is the most reliable indicator of iron status [10, 11].
However, since ferritin rises in inflammatory diseases, the
prevalence of ID is expected to be conservative in case
of inflammation. Sensitivity and specificity of the soluble
transferrin receptor (STFR) were lower in this study com-
pared to the literature; Mast et al. (1998) showed values
of 92% and 84%, respectively [12]. However, their cut-off
value was set at 2.8 mg/l compared to 5 mg/l in our study.
Different study cohorts, cut-off values and test kits may
have contributed to this discrepancy. Nevertheless, STFR
may be used as an additional marker to discern ID in in-
flammatory disease as suggested by Mast et al. (1998) [12].
Renal failure (RF) as defined here can be causally linked
to anaemia according to literature [5]. In a 2004 survey,
almost half (47.7%) of patients with RF were anaemic
(haemoglobin <120 g/l in women and <130 g/l in men >18
years). Regarding ID, about every tenth of our patient cases
with ID showed renal failure. Seen from the perspective of
renal failure (CrCl <30 ml/min.), about every second pa-
tient suffers from ID according to a large epidemiological
US study by Hsu et al. (2002) [13].
Cell indices (MCV and MCHC) are well known to signal
ID. In our cohort, a patient with normal indices would have
a one in ten chance of having ID. Conversely, a patient
with hypochromic, microcytic cell indices showed a chance
of seven in ten to have an ID. Similar results have been
found in an English study by Galloway et al. (2006), where
70-80% of patients with an MCV <75 fl were iron defi-
cient [14]. In spite of its low sensitivity, MCV as marker
for ID is cheap, easily implemented and therefore propag-
ated by the WHO; on the other hand laboratory values such
as mean corpuscular haemoglobin (MCH) have been reap-
praised lately as significantly more accurate indicators of
ID compared with MCV even before anaemia is present
[15].
Coding of ID in this study showed a sensitivity of 60%
(ICD-10 diagnosis of ID in laboratory proven ID patients).
The extent that correct coding might influence hospital rev-
enue has yet to be analysed. When looking at the coding
in the sense of quality control, coding of ID was incom-
plete. On one hand, improvement of coding and document-
ation certainly must be envisioned, although to our know-
ledge, literature regarding coding accuracy in ID is rare. On
the other hand, looking at a diagnosis such as syncope, a
recent study from Denmark with more than 5,200 patients
showed a similar prevalence of correct coding for syncope
of 62.7% [16], although using different diagnoses as proxy
might predispose to confounding. To our knowledge, our
study is the first to report the prevalence of correct ICD-10
ID coding in Switzerland.
Although the data used in this study are of good quality,
there are some limitations. First, the study analyses patient
data from a single site and is retrospective in its design
with the concomitant limitations regarding generalisability
and causality. Second, we cannot exclude a certain selec-
tion bias using data from hospitalised patients on wards of
internal medicine compared to other wards such as surgery
or gynaecology and control for confounding factors was
not possible due to the different nature of medical prob-
lems. Third, including patients with inflammatory diseases
may cause underestimation of ID prevalence, since ferritin
levels increase in inflammatory response [17]. Thus, our
results regarding ID prevalence are expected to be on the
conservative side.
Conclusions
In our patient cohort, iron deficiency (ID) is common;
every seventh patient case with iron parameters (IPs) ana-
lysed was iron deficient. According to statistical estimation
about two thirds of cases with ID may not have been dia-
gnosed. Two thirds of patients with ID were treated with
intravenous iron. Based on these results further studies us-
ing a prospective design in order to optimise diagnosis and
treatment of patients with ID are warranted.
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Figures (large format)
Figure 1
Case inclusion algorithm.
* At least ferritin was determined. †Indices = cellular indices such as haemoglobin, mean corpuscular volume (MCV) or the mean cellular
haemoglobin concentration (MCHC) ‡ Basic parameters: age, gender, main diagnosis, results of red blood cell count (RBCC) § Number of
patients with and without iron parameters do not add up to 1930, because 74 patients had in some cases iron parameters determined and in
others not.
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